



June 19, 2020

To whom it may concern:

Company Name TOHO HOLDINGS CO., LTD.

Corporate Norio Hamada, Chairman of the Board and Chief Executive Officer (CEO),

Representative Director

(First Section of Tokyo Stock Exchange

Securities Code:8129)

Contact: Makoto Kawamura, Director and General

Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Launch of 7 Ingredients / 22 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Chief Executive Officer (CEO), Representative Director: Norio Hamada) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has launched 7 ingredients / 22 products of generic drugs today on June 19, 2020 as below.

New products list

Class	Product Name	Original Brand Name
Cholesterol absorption inhibitor from small intestine Therapeutic agent for hyperlipemia	Ezetimibe Tablets 10mg "KMP"	Zetia Tablets 10mg
Extended-release selective histamine H1 antagonist / therapeutic agent for allergic disease	Levocetirizine hydrochloride Tablets 5mg "KMP"	Xyzal Tablets 5mg
NMDA receptor antagonist Therapeutic agent for Alzheimer dementia	Memantine hydrochloride Tablets 5mg/10mg/20mg "KMP"	MEMARY TABLETS 5mg/10mg/20mg
	Memantine hydrochloride OD Tablets 5mg/10mg/20mg "KMP"	MEMARY OD TABLETS 5mg/10mg/20mg
	Memantine hydrochloride Tablets 5mg/10mg/20mg "TOWA"	MEMARY TABLETS 5mg/10mg/20mg
	Memantine hydrochloride OD Tablets 5mg/10mg/20mg "TOWA"	MEMARY OD TABLETS 5mg/10mg/20mg
Therapeutic agent for Alzheimer dementia	Galantamine hydrobromide OD Tablets 4mg/8mg/12mg "TOWA"	Reminyl OD Tablets 4mg/8mg/12mg
Improving agent for urination disorders associated with benign prostatic hyperplasia (Phosphodiesterase-5 inhibitor)	Tadalafil OD Tablets 2.5mg/5mg ZA "TOWA"	Zalutia Tablets 2.5 mg/5mg
5-alpha-reductase inhibitor Therapeutic agent for benign prostatic hyperplasia	Dutasteride Capsules 0.5mg AV "TOWA"	Avolve Capsules 0.5mg
Therapeutic agent for overactive bladder	Imidafenacin Tablets 0.1mg "YD"	URITOS Tablets 0.1mg STAYBLA Tablets 0.1mg
	Imidafenacin OD Tablets 0.1mg "YD"	URITOS OD Tablets 0.1mg STAYBLA OD Tablets 0.1mg